Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GEM 333

Next Previous
Search
Drug Profile

GEM 333

Alternative Names: CD3XCD33 Bispecific Antibody - Celgene Corporation/AvenCell Europe; GEM333

Latest Information Update: 28 Jun 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celgene Corporation; GEMoaB Monoclonals
  • Developer AvenCell Europe; Celgene Corporation
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Acute myeloid leukaemia

Most Recent Events

  • 28 Jun 2023 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Second-line therapy or greater) in Germany (IV, Infusion)
  • 14 Jun 2022 AvenCell terminates phase-I trial in Acute myeloid leukaemia (Second-line therapy or greater) in Gremany (IV, infusion) in June 2022 due to inability of actions and measures to restart the trial (EudraCT2017-001707-77; GEM333-01; NCT03516760)
  • 28 May 2021 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Refractory metastatic disease) in Germany (IV, Infusion)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top